Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)

Phase 3

ASTRAZENECA PLC (AZNCF)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Chronic Obstructive Pulmonary Disease

View Full Landscape

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease

Clinical Trial

NCT01572792

Last updated: 3/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/20/2012

Bretaris Genuair

Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

View on EMA

EMA7/20/2012

Eklira Genuair

Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Biotechnology•North America•NASDAQ

Related Pipeline

Quetiapine SRPhase 3

Anxiety Disorders

MEDI3250Phase 3

Healthy Japanese Children Age 2 Years Through 6 Years